HSBC Opens Coverage on Waters With Buy Rating, Sees BD Deal as Growth Catalyst
HSBC has started coverage of Waters Corp. with a Buy recommendation and a $460 price objective, arguing that Waters' planned acquisition of Becton Dickinson's Biosciences and Diagnostic Solutions business could unlock significant value. The firm highlights mid-teens earnings growth driven by equipment replacement demand, revenue and cost synergies …